


Membrane Biology:
**Common Gating of Both CLC Transporter
Subunits Underlies Voltage-dependent
Activation of the $2\text{Cl}^-/1\text{H}^+$ Exchanger
CLC-7/Ostm1**



Carmen F. Ludwig, Florian Ullrich, Lilia
Leisle, Tobias Stauber and Thomas J. Jentsch
J. Biol. Chem. 2013, 288:28611-28619.
doi: 10.1074/jbc.M113.509364 originally published online August 27, 2013

Access the most updated version of this article at doi: [10.1074/jbc.M113.509364](https://doi.org/10.1074/jbc.M113.509364)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](#).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 59 references, 27 of which can be accessed free at
<http://www.jbc.org/content/288/40/28611.full.html#ref-list-1>

Common Gating of Both CLC Transporter Subunits Underlies Voltage-dependent Activation of the $2\text{Cl}^-/1\text{H}^+$ Exchanger CIC-7/Ostm1*

Received for publication, August 9, 2013, and in revised form, August 27, 2013. Published, JBC Papers in Press, August 27, 2013, DOI 10.1074/jbc.M113.509364

Carmen F. Ludwig^{‡§}, Florian Ullrich^{‡§}, Lilia Leisle^{‡§1}, Tobias Stauber^{‡§}, and Thomas J. Jentsch^{‡§12}

From the [‡]Leibniz-Institut für Molekulare Pharmakologie (FMP) and [§]Max-Delbrück-Centrum für Molekulare Medizin (MDC), D-13125 Berlin and the ¹NeuroCure Cluster of Excellence, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany

Background: CIC-7 is a homodimeric lysosomal chloride transporter important for lysosomal function and bone degradation.

Results: Altered gating kinetics of one subunit affect the kinetics of the other subunit.

Conclusion: Gating of CIC-7 involves both CLC subunits and requires noncovalent binding of cytoplasmic domains.

Significance: Osteopetrosis and lysosomal storage disease are associated with accelerating mutations in the CIC-7 C terminus and the contacting intramembrane part.

CLC anion transporters form dimers that function either as Cl^- channels or as electrogenic Cl^-/H^+ exchangers. CLC channels display two different types of “gates,” “protopore” gates that open and close the two pores of a CLC dimer independently of each other and common gates that act on both pores simultaneously. CIC-7/Ostm1 is a lysosomal $2\text{Cl}^-/1\text{H}^+$ exchanger that is slowly activated by depolarization. This gating process is drastically accelerated by many *CLCN7* mutations underlying human osteopetrosis. Making use of some of these mutants, we now investigate whether slow voltage activation of plasma membrane-targeted CIC-7/Ostm1 involves protopore or common gates. Voltage activation of wild-type CIC-7 subunits was accelerated by co-expressing an excess of CIC-7 subunits carrying an accelerating mutation together with a point mutation rendering these subunits transport-deficient. Conversely, voltage activation of a fast CIC-7 mutant could be slowed by co-expressing an excess of a transport-deficient mutant. These effects did not depend on whether the accelerating mutation localized to the transmembrane part or to cytoplasmic cystathionine- β -synthase (CBS) domains of CIC-7. Combining accelerating mutations in the same subunit did not speed up gating further. No currents were observed when CIC-7 was truncated after the last intramembrane helix. Currents and slow gating were restored when the C terminus was co-expressed by itself or fused to the C terminus of the β -subunit Ostm1. We conclude that common gating underlies the slow voltage activation of CIC-7. It depends on the CBS domain-containing C terminus that does not require covalent binding to the membrane domain of CIC-7.

The CLC gene family, first identified by the cloning of the voltage-dependent Cl^- channel CIC-0 from *Torpedo* electric organ (1), not only encodes Cl^- channels, but also encodes

anion/proton exchangers (2–5). Both CLC Cl^- channels and Cl^-/H^+ exchangers function as homodimers with one ion translocation pathway per pore, as shown by mutational structure/function analysis (6–8) and x-ray crystallography of prokaryotic and algal CLC proteins (9, 10). Four of the nine mammalian CLC proteins associate with distinct small accessory subunits that display one or two transmembrane domains (11–13). For instance, the lysosomal $2\text{Cl}^-/1\text{H}^+$ exchanger CIC-7 requires binding to the type-I transmembrane protein Ostm1 for protein stability and ion transport activity (12, 14).

The ion transport activity of both CLC Cl^- channels and Cl^-/H^+ exchangers can strongly depend on the transmembrane voltage. Voltage-dependent gating has been most thoroughly studied with the fish CIC-0 Cl^- channel. Macroscopic currents and single-channel analysis provided clear evidence for two distinct gating processes in CIC-0: a fast, depolarization-activated protopore gate acting independently on each of the two pores of the dimer and a slow, hyperpolarization-activated common gate closing both pores simultaneously (15–17). Likewise, mammalian CIC-1 and CIC-2 display protopore and common gating, but their time constants and voltage dependences, as well as the low single-channel conductances of these channels, render the identification and separation of these gating modes more difficult (18–22). The crystal structure of bacterial EcCIC-1, together with mutagenesis, showed that a certain “gating” glutamate, whose side chain protrudes into the ion translocation pathway, plays a pivotal role in protopore gating of CLC channels (23) and in Cl^-/H^+ coupling of CLC exchangers (5), findings that were amply confirmed in other studies with prokaryotic and eukaryotic CLCs. The structural basis of common gating is much less understood, but the gating glutamate may also play a role in closing the permeation pathway after a common rearrangement of both subunits (24, 25). Early mutagenesis studies have implicated the cystathionine- β -synthase (CBS)³ domain-containing C terminus of CIC-0 in its

* This work was supported, in part, by grants from the Deutsche Forschungsgemeinschaft (JE164/7, JE164/9, and SFB740 TP C5).

¹ Present address: University of Iowa, Iowa City, 52242 IA.

² To whom correspondence should be addressed: FMP/MDC, Robert-Rössle-Strasse 10, D-13125 Berlin, Germany. Fax: 49-30-9406-2960; E-mail: Jentsch@fmp-berlin.de.

³ The abbreviations used are: CBS, cystathionine- β -synthase; CT, C terminus; td, transport-deficient.

Common Gating of the Lysosomal CLC-7/Ostm1 Anion Transporter

slow common gating (26), and more recent studies revealed C-terminal movements during common gating of CLC-0 and CLC-1 (27, 28). However, mutations in other regions also affect common gating. For instance, the C212S mutation that totally abolishes slow gating of CLC-0 (29) involves a residue close to the extracellular face of the transmembrane segment.

The mammalian CLC Cl^-/H^+ exchangers (CLC-3 through CLC-7), which are predominantly expressed in the endosomal-lysosomal system (30), are strongly voltage-dependent and mediate measurable ion transport only at positive cytoplasmic potentials (14, 31–34). As currents mediated by CLC-3 through CLC-6 respond very quickly to changes in membrane potential, it is difficult to attribute their voltage dependence either to a gating process that turns the ion exchange on and off or to an intrinsic voltage dependence of the exchange process. Using a plasma membrane-targeted mutant of the lysosomal CLC-7 anion/proton exchanger (35), we recently found that CLC-7/Ostm1 currents respond very slowly to voltage changes (14). These slow current relaxations enabled us to show that the strong outward rectification of CLC-7/Ostm1 is owed to a voltage-dependent gating of the $2\text{Cl}^-/\text{H}^+$ exchange process that intrinsically shows an almost linear voltage dependence (14). Mutations either in CLC-7 or in its β -subunit Ostm1 lead to osteopetrosis, lysosomal storage disease, and neurodegeneration in mice and humans (12, 36–39). Interestingly, several human *CLCN7* mutations identified in osteopetrosis drastically accelerate the gating of CLC-7/Ostm1, suggesting that slow gating may be needed for its physiological function (14). Several of these mutations affect residues in the cytoplasmic CBS domains or in nearby loops of the membrane part of CLC-7. In the present work, we use some of these accelerating mutations, in combination with other mutants and biophysical analysis, to show that the gating of CLC-7/Ostm1 involves the common gate. By extension, these findings probably also apply to the other mammalian $2\text{Cl}^-/\text{H}^+$ exchangers in which gating cannot be studied easily.

EXPERIMENTAL PROCEDURES

Expression Constructs—All constructs for heterologous expression in *Xenopus laevis* oocytes were cloned into the pTLN expression vector (40) as described (14). Point mutations, insertions, and deletions were introduced into human CLC-7 by recombinant PCR. All constructs were confirmed by sequencing the complete open reading frame. To delete the CLC-7 C terminus, a stop codon was introduced at position 624 (CLC-7_{C624X}, or CLC-7_{ΔCT} for short). C-terminal residues 617–805 were either expressed as a *bona fide* soluble protein (CLC-7_{CT}) or fused to the last amino acid of Ostm1 (Ostm1-CLC-7_{CT}).

Voltage Clamp of *X. laevis* Oocytes—*X. laevis* oocytes were injected with cRNA transcribed as described (14) using the mMACHINE kit (Ambion) according to the following scheme: WT (wild-type hCLC-7) + Ostm1, 23 ng + 23 ng; fast gating mutant + Ostm1, 23 ng + 23 ng; WT + fast gating mutant/E314A + Ostm1, 7 ng + 28 ng + 12 ng; fast gating mutant + E314A + Ostm1, 7 ng + 28 ng + 12 ng; CLC-7_{ΔCT} + Ostm1, 15 ng + 15 ng; CLC-7_{ΔCT} + CLC-7_{CT} + Ostm1, 15 ng + 15 ng + 15 ng; CLC-7_{ΔCT} + Ostm1-CLC-7_{CT}, 23 ng + 23 ng; insertion/deletion mutants + Ostm1, 23 ng + 23

ng. Oocytes were kept for 3 days at 17 °C before currents were measured using a two-electrode voltage clamp employing TurboTEC amplifiers (npi electronic GmbH, Tamm, Germany) and pClamp 10 Software (Molecular Devices). Oocytes were superfused with ND96 saline (96 mM NaCl, 2 mM potassium gluconate, 1.8 mM calcium gluconate, 1 mM magnesium gluconate, 5 mM HEPES, pH 7.5). In some experiments, NaCl was replaced with equimolar amounts of NaNO₃. Currents were evoked by clamping the cells for 2 s to voltages between –80 mV and 80 mV in 20-mV steps followed by a repolarizing step to –80 mV for 500 ms. Leak and capacitive currents were not compensated for, but in the figures, capacitive transients were removed for clarity. Time constants of activation and deactivation were obtained from monoexponential fits to the current trace from 25 to 275 ms after the voltage step to 80 mV or to –80 mV following a 2-s pulse to 80 mV, respectively. To determine relative nitrate conductance, the same oocyte was measured both in standard ND96 and in ND96 in which Cl^- was replaced by NO_3^- . Current amplitudes at 80 mV were normalized to the ones in standard ND96.

RESULTS

As common gating is associated with a coordinate conformational change of both subunits of functional CLC dimers, mutations altering common gating may affect the gating of a wild-type (WT) subunit when present in just one subunit of a WT/mutant heteromer. Indeed, *CLCN1* mutations identified in patients with dominant myotonia that shift the voltage of half-maximal activation ($V_{1/2}$) of homodimeric CLC-1 also shifted the voltage dependence of WT subunits in WT/mutant heteromers (41) by changing common gating (18). In a more extreme case, the slow activation by hyperpolarization of CLC-2 was abolished in CLC-1/CLC-2 heterodimeric channels (40). We therefore argued that human *CLCN7* mutations that lead to faster gating in CLC-7 homodimers (14) should accelerate gating of WT subunits in WT/mutant heterodimers if the activation process involves a common gate. However, changed gating kinetics of different subunits are difficult to disentangle upon 1:1 co-expression of WT and fast mutant subunits as we have to deal with a 1:2:1 mixture of WT/WT, WT/mutant, and mutant/mutant subunits. One may try to solve this problem by forcing the formation of heterodimers by constructing concatemers. Although this approach was successfully applied previously in mixing CLC subunits of different unitary conductances (6, 8, 42), gating kinetics may easily be changed by linking the C terminus of one subunit to the amino terminus of the second one. Indeed, a human CLC-7 frameshift mutant (G796fs) (43) that replaced the last 10 C-terminal residues by 129 foreign ones accelerated CLC-7 gating (14).

We therefore opted to combine in a single subunit a fast mutation with another mutation that abolishes ion transport through the same subunit (see scheme in Fig. 1A). Co-expression of this virtually fast, but transport-deficient (“td”) mutant at molar excess with WT subunits should result in currents that are dominated by WT subunits present in CLC-7/CLC-7_{fast,td} heteromers. We used the E314A mutation, which will be further referred to as td, to abolish CLC-7/Ostm1 transport activity (14). This mutation neutralizes a “proton glutamate” at the




FIGURE 1. Experimental design and controls. *A*, schematic presentation of CLC transporter dimers. Each monomer contains an ion permeation pathway. WT subunits are shown in *white*, subunits with an accelerating point mutation are in *gray*, and subunits carrying a transport-abolishing point mutation (td; E314A in CLC-7) are symbolized by a lack of the central “hole.” From left, WT/WT, fast/fast, WT/fast, and WT/(fast,td) dimers. *B*, subunits carrying the transport-deficient td mutation do not contribute to currents in WT/td heteromers as probed by differences in nitrate selectivity of WT (round hole) and S204P (square hole) CLC-7 subunits, as indicated by nitrate selectivity of currents that is indistinguishable between S204P/S204P and S204P/td dimers. *Thick lines* in data point clouds indicate arithmetic mean, and *thin lines* indicate \pm S.E. *C*, representative voltage clamp traces. The td mutation abolishes currents not only when inserted into WT subunits, but also when inserted into subunits containing the R286Q (*lower left trace*) or R762Q (*lower right trace*) mutations. *D*, topology model of CLC-7 showing the localization of the fast mutations CLC-7_{R286Q}, CLC-7_{R762Q}, CLC-7_{R762L}, and CLC-7_{R767Q}. All these mutations underlie human osteopetrosis. *E*, mutations mapped into the crystal structure of algal CmClC. The transmembrane domain is shown in *light gray*, and the CBS domains are in *dark gray*. Positions of the gating (Glu-247 in CLC-7, Glu-210 in CmClC) and proton (Glu-314 in CLC-7, Thr-269 in CmClC) glutamates and of residues Arg-286, Arg-762, and Arg-767 (in CLC-7, corresponding to Leu-241, Val-680, and Ser-685, respectively, in CmClC) are shown as *black spheres*, for clarity only in one of the two subunits.

cytoplasmic face of the transmembrane part of CLC-7 that is thought to be required for the transport of cytoplasmic protons to the Cl^-/H^+ exchange site at the gating glutamate (44). Mammalian Cl^-/H^+ exchangers carrying such proton glutamate mutations do not measurably transport Cl^- either (14, 34, 42), probably because Cl^- lacks its exchange partner. This mechanism suggests that the block of ion transport is confined to subunits carrying the td mutation. Although not indicated in the following text, all CLC-7 subunits additionally carried the L23A,L24A and L68A,L69A mutations in N-terminal AP- and GGA-binding sites, respectively, which lead to partial plasma membrane localization of CLC-7 (14, 35). Furthermore, all constructs were co-expressed with the essential β -subunit Ostm1 (12, 14).

We first performed several control measurements to validate our experimental strategy. To confirm that currents of CLC-7/CLC-7_{td} heteromers were only carried by subunits not containing the td mutation, we exploited the effect of the pore mutation S204P that selectively increases nitrate conductance (14, 45, 46). Coexpression of CLC-7_{S204P} with a molar excess of CLC-7_{td} gave rise to currents whose nitrate selectivity was indistinguishable from that of CLC-7_{S204P} homomers (Fig. 1*B*). Hence the td mutation abolishes currents only in the subunit in which it has been inserted, and this effect does not require that the


adjacent subunit of the dimer also carries this mutation. In other control experiments, we ascertained that the td mutation abolished CLC-7 transport activity also when present together with the accelerating mutations R762Q or R286Q in the same subunit (Fig. 1*C*).

For our analysis, we chose three previously characterized (14) fast mutants of CLC-7: R762Q (36) and R767Q (47), mutations in the second CBS domain found in patients with recessive infantile osteopetrosis, and R286Q, which changes a residue in the intracellular loop between intramembrane helices F and G and that has been found in dominant osteopetrosis (47) (for localization of these mutations, see Fig. 1, *D* and *E*). We co-injected oocytes with CLC-7 and CLC-7_{fast,td} cRNAs at a 1:4 ratio (Fig. 2). CLC-7 currents were elicited by 2-s voltage steps to 80 mV. Activation and deactivation kinetics were determined by fitting single exponential equations to currents at the beginning and at the end of the depolarizing voltage step, respectively. Although present in a transport-deficient CLC-7_{td} subunit, all three fast mutations (R286Q, R762Q, and R767Q) markedly accelerated the activation kinetics of CLC-7 currents *in trans* through the attached WT subunit in CLC-7/CLC-7_{td,fast} heteromers. This acceleration did not reach the same levels as observed with homomeric CLC-7_{fast}/CLC-7_{fast} transporters (Fig. 2, *A–D*). However, this apparent difference in kinetics is at least

Common Gating of the Lysosomal *ClC-7/Ostm1* Anion Transporter

partially owed to currents from WT *ClC-7/ClC-7* homodimers, which are estimated to contribute about 20% with our 1:4 *ClC-7:ClC-7_{td,fast}* co-injection scheme. In the reverse experiment, we asked whether *ClC-7_{fast}* currents could be slowed down *trans* by 1:4 co-expression with *ClC-7_{td}* mutants. This was

indeed the case, and gating kinetics were similar between *ClC-7/ClC-7_{fast,td}* and *ClC-7_{fast/ClC-7_{td}}* expression schemes for all three accelerating mutants (Fig. 2, *A–D*). Likewise, deactivation kinetics of *ClC-7* were accelerated *trans* by *ClC-7_{td,fast}* mutants (Fig. 2, *E–G*). In control experiments, *ClC-7_{td}* did not






FIGURE 3. Insertion of two fast mutations into the same subunit does not accelerate gating further. *A*, original recordings of homodimeric CIC-7 transporters containing the fast mutations R286Q (in the transmembrane domain), R762Q (in CBS2), and R286Q,R762Q double mutants in comparison with wild-type CIC-7. The voltage clamp protocol is as in Fig. 1. *B*, individual and averaged activation time constants (τ_{act}) obtained from those experiments. *Thick lines* indicate arithmetic mean, and *thin lines* indicate \pm S.E. The β -subunit Ostm1 was always co-expressed.

affect gating kinetics of co-injected CIC-7, and CIC-7_{fast}/CIC-7_{td,fast} displayed gating kinetics similar to CIC-7_{fast} (Fig. 2).

We next asked whether we could further accelerate CIC-7 gating by inserting two fast mutations into the same subunit. We generated the CIC-7 R286Q,R762Q, R286Q,R767Q, and R762Q,R767Q double mutants, out of which only CIC-7_{R286Q,R762Q} gave rise to robust currents (Fig. 3*A*). Time constants of activation of CIC-7_{R286Q,R762Q} and CIC-7_{R762Q} did not differ from each other, showing that the effects of these mutations were not additive (Fig. 3*B*).

Most mutations accelerating the gating of CIC-7 localize to the interface between the cytosolic C terminus and transmembrane domains, where they are thought to disturb gating-relevant interactions (14). On the other hand, the CBS domain-containing C terminus of CIC-7 is covalently attached to intramembrane helix R, which directly coordinates a Cl⁻ ion in

the CLC pore through the side chain of a tyrosine close to its N terminus (9). It is tempting to speculate that the CIC-7 C terminus influences gating by changing the position of the R-helix. We therefore asked whether the length of the R-CBS1-linker might influence CIC-7 gating. Both deletion and insertion of several amino acids after threonine 621 (Fig. 4*A*) indeed accelerated gating, whereas deleting 6 amino acids abolished CIC-7/Ostm1 transport function (Fig. 4, *B* and *C*).

These results seemed to support the hypothesis that CBS domains modulate gating by “pulling” on the R-helix. We were curious to know what would happen if we entirely eliminated this possibility by disrupting the peptide bond between helix R and CBS1, using a “split transporter” approach akin to the “split channel” approach as used first with the CIC-1 Cl⁻ channel (48). Expression of a CIC-7 mutant truncated shortly after the R-helix and thus lacking both CBS domains (CIC-7_{ΔCT}) did not yield currents (Fig. 5, *A* and *B*).

Surprisingly, currents of CIC-7_{ΔCT} could be rescued by co-expressing the cytoplasmic C terminus (CIC-7_{CT}) from a separate cRNA (Fig. 5, *A* and *B*). Resulting currents reached amplitudes similar to WT CIC-7, but their activation kinetics were slightly faster (Fig. 5, *B* and *C*). Instead of expressing the C terminus only as a soluble protein, we also fused it to the obligate CIC-7 β -subunit Ostm1 directly after its last residue to anchor it to the plasma membrane in close vicinity to the CIC-7 backbone. Co-expressing this fusion protein (Ostm1-CIC-7_{CT}) with CIC-7_{ΔCT} (without additional WT Ostm1) yielded currents that were indistinguishable from WT CIC-7/Ostm1 in their kinetics (Fig. 5*C*) and often reached similar amplitudes. We also inserted the fast R762L mutation into CBS2 of the isolated C terminus CIC-7_{CT} and into the Ostm1-CIC-7_{CT} fusion protein. Although the combination of CIC-7_{ΔCT} + CIC-7_{CT(R762L)} failed to yield currents (data not shown), split channels in which the mutant C terminus was attached to Ostm1 (CIC-7_{ΔCT} + Ostm1-CIC-7_{CT(R762L)}) produced robust currents that displayed activation time constants indistinguishable from the fast mutant CIC-7_{R762L} + Ostm1 (Fig. 5*C*). We conclude that the role of the CIC-7 C terminus in CIC-7 gating does not depend on a covalent linkage to the last intramembrane helix R.

In view of these results, we re-examined the effects of linker deletions (Fig. 4) and expressed split transporters in which the polypeptide chain following helix R was truncated at different positions (Fig. 5*D*). These experiments revealed that gating kinetics became significantly faster when CIC-7 was truncated at position 621 or earlier. Hence the results of our linker shortening might be owed to specific effects of deleting particular

FIGURE 2. Gating kinetics of ion flux through a CIC-7 monomer are influenced by the adjacent subunit of the dimer. *A*, effect of the fast R762Q mutation that affects a residue in the second CBS domain. Original voltage clamp traces from oocytes injected with RNA encoding WT CIC-7, CIC-7_{R762Q}, a 1:4 ratio of WT and CIC-7_{R762Q,E314A} RNA, and a 1:4 co-injection of the fast CIC-7_{R762Q} mutant with the E314A (td) mutant that renders the subunit transport-deficient are shown. The voltage clamp protocol is as in Fig. 1. Symbols above diagrams are as follows: WT subunits are shown in white, subunits with an accelerating point mutation are in gray, and subunits carrying a transport-abolishing point mutation (td; E314A in CIC-7) are symbolized by a lack of the central “hole.” *B*, individual and averaged activation time constants (τ_{act}) obtained from experiments as shown above. Note that transport-deficient fast subunit accelerates gating in dimers with a WT subunit and that the transport-deficient WT subunit slows gating in dimers with a fast subunit, resulting in indistinguishable gating kinetics. *C* and *D*, similar experiments obtained with R767Q, another accelerating mutant in CBS2 (*D*), and with the fast R286Q mutation at the intracellular side of helix G of the membrane part of CIC-7 (*D*). *E*, individual and averaged deactivation time constants (τ_{deact}) of the investigated fast mutant CIC-7_{R762Q}. *F* and *G*, similar experiment for CIC-7_{R767Q} (*F*) and CIC-7_{R286Q} (*G*). Oocytes in *E–G* were the same as used in *B–D*. In all experiments, mRNA for the β -subunit Ostm1 was co-injected. *Thick lines* indicate arithmetic mean and *thin lines* indicate \pm S.E. *** indicates a *p* value < 0.001 calculated by Student’s *t* test between WT and WT+(fast,td), and between fast and td+fast.

Common Gating of the Lysosomal CIC-7/Ostm1 Anion Transporter




FIGURE 4. CIC-7/Ostm1 activation kinetics depend on the length of the linker between the transmembrane domain and CBS1. *A*, diagram showing the sequence of the linker between the last intramembrane helix R and CBS1. Deletion and insertion constructs are shown. *B*, typical two-electrode voltage clamp traces obtained with these constructs upon co-expression with Ostm1. *C*, evaluation of corresponding activation (τ_{act}) and deactivation (τ_{deact}) time constants. The voltage clamp protocol is as in Fig. 1. *Thick lines* indicate arithmetic mean, and *thin lines* indicate \pm S.E.




FIGURE 5. The CIC-7 C terminus is crucial for CIC-7 function and can be supplied as a separate polypeptide chain. *A*, typical recordings of oocytes expressing CIC-7 $_{\Delta CT}$ in which CIC-7 is truncated shortly after the last membrane helix and of oocytes co-expressing this mutant with either the C terminus (CIC-7 $_{CT}$) or a chimeric protein (Ostm1-CIC-7 $_{CT}$) in which the C terminus is fused to the β -subunit Ostm1. WT Ostm1 was co-expressed in the first two cases. The voltage clamp protocol is as in Fig. 1. *B*, mean near steady-state current-voltage relationships (evaluated at 2 s after voltage steps) obtained from truncated constructs compared with controls. *C*, activation time constants (τ_{act}) of currents from experiments as above, and from CIC-7 $_{\Delta CT}$ + Ostm1-CIC-7 $_{CT-R762L}$ in which a CIC-7 C terminus carrying the fast mutation R762L in CBS2 is fused to the Ostm1 β -subunit. *D*, activation time constants of WT CIC-7 compared with split transporters in which the truncation point after helix R is varied. CIC-7 $_{1-623}$ corresponds to CIC-7 $_{\Delta CT}$. Constructs were always co-expressed with CIC-7 $_{CT}$ and with Ostm1. *Thick lines* indicate arithmetic mean, and *thin lines* indicate \pm S.E. Significance levels (one-way analysis of variance): ***, $p < 0.001$.

amino acids, although the mechanism by which this changes gating remains unclear.

DISCUSSION

A fascinating aspect of the CLC family is that its members transport ions in modes traditionally thought to be radically different; they function either as ion channels or as strictly coupled ion exchangers. However, remnants of an ion exchange activity can be found in CLC Cl^- channels because the gating of CLC-0 may be associated with H^+ transport (49). Further, the strong voltage dependence of Cl^-/H^+ exchange activity of vesicular CLCs resembles the gating of ion channels, as recently demonstrated for plasma membrane-expressed CLC-7 (14). The intrinsically almost linear anion/proton exchange activity of this transporter is very slowly turned on by depolarization in a process that strongly resembles gating of ion channels.

We now asked whether the gating of CLC-7/Ostm1 resembles the CLC-0 protopore gate, which affects one pore at a time, or its common gate, which closes both pores of the double-barreled channel simultaneously. We argued that mutations accelerating CLC-7 gating might impose their faster gating kinetics on associated WT subunits in heterodimers if the gating process involves both subunits. We devised experiments in which one of the subunits of the dimer was rendered transport-deficient by another mutation to better isolate the effect on the currents of the other subunit. Such transport-deficient mutants indeed partially imposed their gating kinetics on the other, transporting subunit, rendering their activation and deactivation faster or slower, depending on the particular combination. These results resemble previous work in which dominant CLC-1 mutants partially imposed their shifted voltage dependence (as observed in homomeric channels) on the gating of heteromers through an effect on common gating (18, 41). We conclude that voltage-dependent activation of CLC-7/Ostm1 prominently involves common gating of both subunits. A minor contribution of protopore gating, however, cannot be excluded.

Many accelerating mutations cluster in cytoplasmic CBS domains and the cytoplasmic surface of the CLC-7 transmembrane segment (14), suggesting that interactions between these parts of the protein influence gating. We have also explored another possible mechanism by which mutations in the C terminus could affect gating, *i.e.* through a direct “pull” of the C terminus on the last intramembrane helix R. This speculation is attractive because the N-terminal part of helix R participates in coordinating a Cl^- ion in a binding site in the permeation pathway as revealed by crystal structures of prokaryotic CLCs (9, 23). Consistent with this idea, Förster resonance energy transfer (FRET) experiments using CLC-0 and CLC-1 to whose C termini GFP variants had been fused indicated large movements of those domains during gating (27, 28). Although initial experiments in which we varied the length of the R helix-CBS1 linker seemed to support this hypothesis, our subsequent split transporter experiments clearly indicated that this is not the case.

These split transporter experiments indicated that the CLC-7 C terminus binds efficiently to the CLC-7 backbone even without being anchored nearby at the plasma membrane (as in the Ostm1-CLC-7_{CT} fusion protein). The crystal structure of the

CBS domain-containing algal CLC (10) suggests that this binding prominently involves CBS2, a domain in which several osteopetrosis-causing mutations were found (14, 36, 43, 47). The similar gating kinetics of currents obtained from WT and CLC-7_{ΔCT} co-expressed with either Ostm1-CLC-7_{CT} or the detached C terminus CLC-7_{CT} suggest that the C terminus does not fully dissociate from the CLC-7 backbone during gating because its dilution in the cytoplasm is expected to severely slow down its reassociation. This should then be accompanied by a severe deceleration of either activation or deactivation, depending on whether the binding of the C terminus “closes” or “opens” the transporter, respectively. Interestingly, when we inserted fast mutations into CBS2, we observed functional split transporters only when the mutated C terminus was attached to Ostm1 (Fig. 5C), but not when it was supplied as a soluble protein. Hence these mutations may destabilize the binding of the C terminus to the transporter backbone with reasonably efficient binding occurring only when the local concentration of the C terminus is drastically increased by tethering it to Ostm1.

Split channel (respectively, transporter) approaches have been used previously with CLC-0 (50), CLC-1 (48, 51–54), and CLC-5 (55). These studies agreed in that the function of CLC proteins that were truncated after CBS1 could be rescued by co-expressing the missing fragment containing CBS2. This complementation can be easily explained by the tight CBS1-CBS2 binding that was revealed by crystal structures of CLC CBS domains (10, 56). Indeed, CBS domains also form internal dimers in other CBS domain-containing proteins (57). A complementation similar to the one described here, *i.e.* the functional rescue of a CLC truncated directly after the R helix by the complete soluble C terminus, had been tried previously with the skeletal muscle Cl^- channel CLC-1 (48, 54). However, both studies agreed that the co-expression of both fragments failed to yield functional channels. Hence the binding affinity of the backbone to the C-terminal tail seems to be stronger in the case of CLC-7.

Common gating requires a coordinate conformational change of both subunits of the dimer that ultimately leads to an occlusion of the permeation pathway. This necessitates both changes at the interface between both subunits and of residues in the pore region. CLC monomers contact each other not only at their broad membrane-embedded interface (9, 10), but also between the CBS domains of either subunit (10, 58). Consistent with these considerations, FRET detected large movements of CBS domains during common gating of CLC-0 (27), ^{19}F NMR indicated substrate-driven changes in the position of a tyrosine at the membrane-embedded dimer interface of EcCLC-1 (59), and mutations in the gating glutamate in the pore abolish both common and protopore gating of *e.g.* CLC-2 (21). However, our picture of common gating remains appallingly incomplete. In particular, the way in which mutations in CBS domains affect this gating process remains enigmatic.

Many mutations, not just those found in patients with osteopetrosis, accelerate CLC-7 gating, whereas we have not yet obtained CLC-7 mutants that gate more slowly than WT.⁴ Evolution may have maximized the time constant of CLC-7 gating

⁴C. F. Ludwig, F. Ullrich, L. Leisle, T. Stauber, and T. J. Jentsch, unpublished data.

Common Gating of the Lysosomal *ClC-7/Ostm1* Anion Transporter

that is several orders of magnitude slower than with *ClC-3* to *ClC-6*. Together with the fact that many disease-causing mutations accelerate *ClC-7* gating (14), these observations suggest that slow gating of *ClC-7* may be important for its biological function. If accelerated gating by itself were pathogenic, the acceleration of common gating in WT/fast heteromers might contribute to the dominant inheritance pattern of some osteopetrosis-causing *CLCN7* mutations. However, some accelerating mutations may also decrease protein stability, as shown previously (36) for the R762Q mutant we have studied here. Indeed, this particular accelerating mutation was found in a patient with recessive osteopetrosis (36).

In summary, the gating of *ClC-7/Ostm1* bears parallels to the common, slow gate of the *Torpedo* Cl^- channel *ClC-0* that affects both pores of the dimeric channel simultaneously. It depends on the presence of the CBS domain-containing C terminus that interacts with the transmembrane backbone and modulates gating kinetics even in the absence of a covalent link. Our work extends the role of common gating from *CLC* Cl^- channels to Cl^-/H^+ exchangers.

Acknowledgments—We thank P. Seidler, J. Liebold, and S. Zillmann for technical assistance.

REFERENCES

- Jentsch, T. J., Steinmeyer, K., and Schwarz, G. (1990) Primary structure of *Torpedo marmorata* chloride channel isolated by expression cloning in *Xenopus* oocytes. *Nature* **348**, 510–514
- Jentsch, T. J. (2008) *CLC* chloride channels and transporters: From genes to protein structure, pathology and physiology. *Crit. Rev. Biochem. Mol. Biol.* **43**, 3–36
- Stauber, T., Weinert, S., and Jentsch, T. J. (2012) Cell biology and physiology of *CLC* chloride channels and transporters. *Compr. Physiol.* **2**, 1701–1744
- Miller, C. (2006) *ClC* chloride channels viewed through a transporter lens. *Nature* **440**, 484–489
- Accardi, A., and Miller, C. (2004) Secondary active transport mediated by a prokaryotic homologue of *ClC* Cl^- channels. *Nature* **427**, 803–807
- Ludewig, U., Pusch, M., and Jentsch, T. J. (1996) Two physically distinct pores in the dimeric *ClC-0* chloride channel. *Nature* **383**, 340–343
- Middleton, R. E., Pheasant, D. J., and Miller, C. (1996) Homodimeric architecture of a *ClC*-type chloride ion channel. *Nature* **383**, 337–340
- Weinreich, F., and Jentsch, T. J. (2001) Pores formed by single subunits in mixed dimers of different *CLC* chloride channels. *J. Biol. Chem.* **276**, 2347–2353
- Dutzler, R., Campbell, E. B., Cadene, M., Chait, B. T., and MacKinnon, R. (2002) X-ray structure of a *ClC* chloride channel at 3.0 Å reveals the molecular basis of anion selectivity. *Nature* **415**, 287–294
- Feng, L., Campbell, E. B., Hsiung, Y., and MacKinnon, R. (2010) Structure of a eukaryotic *CLC* transporter defines an intermediate state in the transport cycle. *Science* **330**, 635–641
- Estévez, R., Boettger, T., Stein, V., Birkenhäger, R., Otto, E., Hildebrandt, F., and Jentsch, T. J. (2001) Barttin is a Cl^- -channel β -subunit crucial for renal Cl^- -reabsorption and inner ear K^+ -secretion. *Nature* **414**, 558–561
- Lange, P. F., Wartosch, L., Jentsch, T. J., and Fuhrmann, J. C. (2006) *ClC-7* requires *Ostm1* as a β -subunit to support bone resorption and lysosomal function. *Nature* **440**, 220–223
- Jeworutzki, E., López-Hernández, T., Capdevila-Nortes, X., Sirisi, S., Bengtsson, L., Montolio, M., Zifarelli, G., Arnedo, T., Müller, C. S., Schulte, U., Nunes, V., Martínez, A., Jentsch, T. J., Gasull, X., Pusch, M., and Estévez, R. (2012) GlialCAM, a protein defective in a leukodystrophy, serves as a *ClC-2* Cl^- channel auxiliary subunit. *Neuron* **73**, 951–961
- Leisle, L., Ludwig, C. F., Wagner, F. A., Jentsch, T. J., and Stauber, T. (2011) *ClC-7* is a slowly voltage-gated $2\text{Cl}^-/1\text{H}^+$ -exchanger and requires *Ostm1* for transport activity. *EMBO J.* **30**, 2140–2152
- Miller, C., and White, M. M. (1984) Dimeric structure of single chloride channels from *Torpedo* electroplax. *Proc. Natl. Acad. Sci. U.S.A.* **81**, 2772–2775
- Bauer, C. K., Steinmeyer, K., Schwarz, J. R., and Jentsch, T. J. (1991) Completely functional double-barreled chloride channel expressed from a single *Torpedo* cDNA. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 11052–11056
- Ludewig, U., Pusch, M., and Jentsch, T. J. (1997) Independent gating of single pores in *CLC-0* chloride channels. *Biophys. J.* **73**, 789–797
- Saviane, C., Conti, F., and Pusch, M. (1999) The muscle chloride channel *ClC-1* has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. *J. Gen. Physiol.* **113**, 457–468
- Chen, M. F., and Chen, T. Y. (2001) Different fast-gate regulation by external Cl^- and H^+ of the muscle-type *ClC* chloride channels. *J. Gen. Physiol.* **118**, 23–32
- de Santiago, J. A., Nehrke, K., and Arreola, J. (2005) Quantitative analysis of the voltage-dependent gating of mouse parotid *ClC-2* chloride channel. *J. Gen. Physiol.* **126**, 591–603
- Yusef, Y. R., Zúñiga, L., Catalán, M., Niemeyer, M. L., Cid, L. P., and Sepúlveda, F. V. (2006) Removal of gating in voltage-dependent *ClC-2* chloride channel by point mutations affecting the pore and C-terminus CBS-2 domain. *J. Physiol.* **572**, 173–181
- Bennetts, B., Yu, Y., Chen, T. Y., and Parker, M. W. (2012) Intracellular β -nicotinamide adenine dinucleotide inhibits the skeletal muscle *ClC-1* chloride channel. *J. Biol. Chem.* **287**, 25808–25820
- Dutzler, R., Campbell, E. B., and MacKinnon, R. (2003) Gating the selectivity filter in *ClC* chloride channels. *Science* **300**, 108–112
- Traverso, S., Zifarelli, G., Aiello, R., and Pusch, M. (2006) Proton sensing of *ClC-0* mutant E166D. *J. Gen. Physiol.* **127**, 51–65
- Cederholm, J. M., Rychkov, G. Y., Bagley, C. J., and Bretag, A. H. (2010) Inter-subunit communication and fast gate integrity are important for common gating in h*ClC-1*. *Int. J. Biochem. Cell Biol.* **42**, 1182–1188
- Fong, P., Rehfeldt, A., and Jentsch, T. J. (1998) Determinants of slow gating in *ClC-0*, the voltage-gated chloride channel of *Torpedo marmorata*. *Am. J. Physiol.* **274**, C966–C973
- Bykova, E. A., Zhang, X. D., Chen, T. Y., and Zheng, J. (2006) Large movement in the C terminus of *CLC-0* chloride channel during slow gating. *Nat. Struct. Mol. Biol.* **13**, 1115–1119
- Ma, L., Rychkov, G. Y., Bykova, E. A., Zheng, J., and Bretag, A. H. (2011) Movement of h*ClC-1* C-terminus during common gating and limits on their cytoplasmic location. *Biochem. J.* **436**, 415–428
- Lin, Y. W., Lin, C. W., and Chen, T. Y. (1999) Elimination of the slow gating of *ClC-0* chloride channel by a point mutation. *J. Gen. Physiol.* **114**, 1–12
- Stauber, T., and Jentsch, T. J. (2013) Chloride in vesicular trafficking and function. *Annu. Rev. Physiol.* **75**, 453–477
- Friedrich, T., Breiderhoff, T., and Jentsch, T. J. (1999) Mutational analysis demonstrates that *ClC-4* and *ClC-5* directly mediate plasma membrane currents. *J. Biol. Chem.* **274**, 896–902
- Li, X., Shimada, K., Showalter, L. A., and Weinman, S. A. (2000) Biophysical properties of *ClC-3* differentiate it from swelling-activated chloride channels in Chinese hamster ovary-K1 cells. *J. Biol. Chem.* **275**, 35994–35998
- Steinmeyer, K., Schwappach, B., Bens, M., Vandewalle, A., and Jentsch, T. J. (1995) Cloning and functional expression of rat *CLC-5*, a chloride channel related to kidney disease. *J. Biol. Chem.* **270**, 31172–31177
- Neagoe, I., Stauber, T., Fidzinski, P., Bergsdorf, E. Y., and Jentsch, T. J. (2010) The late endosomal *ClC-6* mediates proton/chloride countertransport in heterologous plasma membrane expression. *J. Biol. Chem.* **285**, 21689–21697
- Stauber, T., and Jentsch, T. J. (2010) Sorting motifs of the endosomal/lysosomal *CLC* chloride transporters. *J. Biol. Chem.* **285**, 34537–34548
- Kornak, U., Kasper, D., Bösl, M. R., Kaiser, E., Schweizer, M., Schulz, A., Friedrich, W., Delling, G., and Jentsch, T. J. (2001) Loss of the *ClC-7* chloride channel leads to osteopetrosis in mice and man. *Cell* **104**, 205–215
- Kasper, D., Planells-Cases, R., Fuhrmann, J. C., Scheel, O., Zeitz, O., Ru-

- ether, K., Schmitt, A., Poët, M., Steinfeld, R., Schweizer, M., Kornak, U., and Jentsch, T. J. (2005) Loss of the chloride channel *ClC-7* leads to lysosomal storage disease and neurodegeneration. *EMBO J.* **24**, 1079–1091
38. Chalhoub, N., Benachenhou, N., Rajapurohitam, V., Pata, M., Ferron, M., Frattini, A., Villa, A., and Vacher, J. (2003) Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. *Nat. Med.* **9**, 399–406
 39. Weinert, S., Jabs, S., Supancharit, C., Schweizer, M., Gimber, N., Richter, M., Rademann, J., Stauber, T., Kornak, U., and Jentsch, T. J. (2010) Lysosomal pathology and osteopetrosis upon loss of H^+ -driven lysosomal Cl^- accumulation. *Science* **328**, 1401–1403
 40. Lorenz, C., Pusch, M., and Jentsch, T. J. (1996) Heteromultimeric *ClC* chloride channels with novel properties. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 13362–13366
 41. Pusch, M., Steinmeyer, K., Koch, M. C., and Jentsch, T. J. (1995) Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the *ClC-1* chloride channel. *Neuron* **15**, 1455–1463
 42. Zdebik, A. A., Zifarelli, G., Bergsdorf, E.-Y., Soliani, P., Scheel, O., Jentsch, T. J., and Pusch, M. (2008) Determinants of anion-proton coupling in mammalian endosomal *ClC* proteins. *J. Biol. Chem.* **283**, 4219–4227
 43. Cleiren, E., Bénichou, O., Van Hul, E., Gram, J., Bollerslev, J., Singer, F. R., Beaverson, K., Aledo, A., Whyte, M. P., Yoneyama, T., deVernejoul, M. C., and Van Hul, W. (2001) Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the *ClCN7* chloride channel gene. *Hum. Mol. Genet.* **10**, 2861–2867
 44. Accardi, A., Walden, M., Nguitragool, W., Jayaram, H., Williams, C., and Miller, C. (2005) Separate ion pathways in a Cl^-/H^+ exchanger. *J. Gen. Physiol.* **126**, 563–570
 45. Bergsdorf, E. Y., Zdebik, A. A., and Jentsch, T. J. (2009) Residues important for nitrate/proton coupling in plant and mammalian *ClC* transporters. *J. Biol. Chem.* **284**, 11184–11193
 46. Zifarelli, G., and Pusch, M. (2009) Conversion of the $2 Cl^-/1 H^+$ antiporter *ClC-5* in a NO_3^-/H^+ antiporter by a single point mutation. *EMBO J.* **28**, 175–182
 47. Frattini, A., Pangrazio, A., Susani, L., Sobacchi, C., Mirolo, M., Abinun, M., Andolina, M., Flanagan, A., Horwitz, E. M., Mihci, E., Notarangelo, L. D., Ramenghi, U., Teti, A., Van Hove, J., Vujic, D., Young, T., Albertini, A., Orchard, P. J., Vezzoni, P., and Villa, A. (2003) Chloride channel *ClCN7* mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. *J. Bone Miner. Res.* **18**, 1740–1747
 48. Schmidt-Rose, T., and Jentsch, T. J. (1997) Reconstitution of functional voltage-gated chloride channels from complementary fragments of *ClC-1*. *J. Biol. Chem.* **272**, 20515–20521
 49. Lísal, J., and Maduke, M. (2008) The *ClC-0* chloride channel is a 'broken' Cl^-/H^+ antiporter. *Nat. Struct. Mol. Biol.* **15**, 805–810
 50. Maduke, M., Williams, C., and Miller, C. (1998) Formation of *ClC-0* chloride channels from separated transmembrane and cytoplasmic domains. *Biochemistry* **37**, 1315–1321
 51. Estévez, R., Pusch, M., Ferrer-Costa, C., Orozco, M., and Jentsch, T. J. (2004) Functional and structural conservation of CBS domains from *ClC* chloride channels. *J. Physiol.* **557**, 363–378
 52. Wu, W., Rychkov, G. Y., Hughes, B. P., and Bretag, A. H. (2006) Functional complementation of truncated human skeletal-muscle chloride channel (*hClC-1*) using carboxyl tail fragments. *Biochem. J.* **395**, 89–97
 53. Ma, L., Rychkov, G. Y., Hughes, B. P., and Bretag, A. H. (2008) Analysis of carboxyl tail function in the skeletal muscle Cl^- channel *hClC-1*. *Biochem. J.* **413**, 61–69
 54. Hebeisen, S., Biela, A., Giese, B., Müller-Newen, G., Hidalgo, P., and Fahlke, C. (2004) The role of the carboxyl terminus in *ClC* chloride channel function. *J. Biol. Chem.* **279**, 13140–13147
 55. Mo, L., Xiong, W., Qian, T., Sun, H., and Wills, N. K. (2004) Coexpression of complementary fragments of *ClC-5* and restoration of chloride channel function in a Dent's disease mutation. *Am. J. Physiol. Cell Physiol.* **286**, C79–C89
 56. Meyer, S., and Dutzler, R. (2006) Crystal structure of the cytoplasmic domain of the chloride channel *ClC-0*. *Structure* **14**, 299–307
 57. Ignoul, S., and Eggermont, J. (2005) CBS domains: structure, function, and pathology in human proteins. *Am. J. Physiol. Cell Physiol.* **289**, C1369–C1378
 58. Markovic, S., and Dutzler, R. (2007) The structure of the cytoplasmic domain of the chloride channel *ClC-Ka* reveals a conserved interaction interface. *Structure* **15**, 715–725
 59. Elvington, S. M., Liu, C. W., and Maduke, M. C. (2009) Substrate-driven conformational changes in *ClC-ec1* observed by fluorine NMR. *EMBO J.* **28**, 3090–3102